Journal of Medicinal Chemistry · 1998 · 37 citations · 19 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationEnzyme InhibitionLead Compound DesignLigand BindingLigand-based DesignPotency OptimizationStructure-activity Relationship AnalysisEnzyme Inhibitor DiscoveryEnzyme Inhibitor SynthesisMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesProtease InhibitorsStructure-based Lead DiscoveryStructure-guided Lead DiscoverySubstrate Binding Sites
For most of the known synthetic inhibitors of matrix metalloproteinases (MMPs), a substrate-like binding mode was postulated on the basis of X-ray crystallographic structures of MMP/inhibitor complexes. Conversely, the malonic acid-based inhibitor (2R,S)-HONH-CO-CH(i-Bu)-CO-Ala-Gly-NH2 was found to bind in a surprisingly different manner. Using this compound as a new lead structure, the interaction sites with human neutrophil collagenase (MMP8) were optimized with a series of iteratively designed analogues and with the help of X-ray structural analysis of selected inhibitors to finally produce low molecular weight nonpeptidic compounds of 500-1000-fold improved inhibitory potency.
19
Wolfram Bode, Peter Reinemer, Robert Huber et al. · The EMBO Journal · 1994 · 338 citations
Structure of the Catalytic Domain of Fibroblast Collagenase Complexed with an Inhibitor
Brett Lovejoy, Anne Cleasby, Anne M. Hassell et al. · Science · 1994 · 332 citations
Recent advances in matrix metalloproteinase inhibitor research
R. Paul Beckett, A DAVIDSON, Alan H. Drummond et al. · Drug Discovery Today · 1996 · 282 citations